ASX Health Care Stocks With Buy Ratings Investors Are Watching Now

• Eight ASX healthcare and biotech companies are attracting attention with consensus Buy ratings and important clinical or commercial milestones.

Aditi Sarkar | 29 June 2026

ASX Health Care Stocks with Buy Rating to Watch Out

• Nine ASX healthcare companies are attracting investor interest with Buy ratings and promising growth catalysts.

Aditi Sarkar | 29 June 2026

6 ASX Health Care Stocks with Buy Ratings Investors Are Watching Now

• Unprecedented Demographic Tailwinds: The rapid expansion of the 80+ age demographic across Australia and New Zealand is creating guaranteed long-term demand for ASX aged care stocks and ASX retirement living stocks.

Shwetambri Chauhan | 29 June 2026

Orthocell (ASX:OCC) Share Price Falls 4.61% as Investors Assess MedTech Sector Sentiment

• The company maintained a market capitalisation of approximately A$196 million.

Aditi Sarkar | 29 June 2026

OncoSil Medical (ASX:OSL) Share Price Holds Steady as Investors Monitor MedTech Sector

• The company maintained a market capitalisation of approximately A$21 million.

Aditi Sarkar | 29 June 2026

Mayne Pharma Group (ASX:MYX) Share Price Rises 3.89% as Healthcare Stocks Gain Momentum

• The company maintained a market capitalisation of approximately A$217 million.

Aditi Sarkar | 29 June 2026

Inoviq (ASX:IIQ) Share Price Holds Steady: Why Investors Are Watching the Biotech Stock

• No verified company-specific ASX announcement was identified behind the unchanged share price.

Aditi Sarkar | 29 June 2026

Visionflex Lands on ASX Runner Radar as Investors Hunt the Next Small-Cap Breakout

• ASX: VFX is being watched after investors tracked the company after contract momentum in remote examination technology and virtual care equipment.

Sonal Goyal | 29 June 2026

CSL Faces EU Tavneos Setback, But Analysts Say the Earnings Hit May Be Limited

• CSL (ASX: CSL) faces a European regulatory and label setback for Tavneos (avacopan), held through its CSL Vifor business.

Sonal Goyal | 29 June 2026

Opthea (ASX:OPT)’s High-Stakes Comeback Bid: Can This Beaten-Down ASX Biotech Win Back Investors?

• Opthea (ASX:OPT) is in the market spotlight because of a fresh market-moving catalyst that has changed the investor conversation.

Sonal Goyal | 29 June 2026

Healthcare

ASX Health Care Stocks With Buy Ratings Investors Are Watching Now

ASX Health Care Stocks with Buy Rating to Watch Out

6 ASX Health Care Stocks with Buy Ratings Investors Are Watching Now

Orthocell (ASX:OCC) Share Price Falls 4.61% as Investors Assess MedTech Sector Sentiment

OncoSil Medical (ASX:OSL) Share Price Holds Steady as Investors Monitor MedTech Sector

Mayne Pharma Group (ASX:MYX) Share Price Rises 3.89% as Healthcare Stocks Gain Momentum

Inoviq (ASX:IIQ) Share Price Holds Steady: Why Investors Are Watching the Biotech Stock

Visionflex Lands on ASX Runner Radar as Investors Hunt the Next Small-Cap Breakout

CSL Faces EU Tavneos Setback, But Analysts Say the Earnings Hit May Be Limited

Opthea (ASX:OPT)’s High-Stakes Comeback Bid: Can This Beaten-Down ASX Biotech Win Back Investors?

Latest News

What a US fraud event means for Zip Co (ASX:ZIP) as the ASX 200 lender holds its FY27 guidance

How Xero (ASX:XRO) lifted its FY27 outlook after a Melio-driven first half

Why ASX 200 software group WiseTech Global Ltd (ASX:WTC) still faces scrutiny after ASIC closed its investigations

What the IMDA show cause notice means for Tuas Ltd (ASX:TUA) after a year of record revenue

Why Seek (ASX:SEK) Is Overhauling Its Growth Fund as the ASX 200 Jobs Marketplace Leans on Pricing

Why ASX 200 property portal REA Group (ASX:REA) is leaning on pricing as listings soften